Biosimilars stocks
바이오시밀러
What are Biosimilars stocks in Korea?
The Biosimilars theme on jonbur groups 13 Korean stocks listed on KOSPI and KOSDAQ, worth ₩138T in total. On Oct 29, 2026 the group moved down 0.64% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 13
- Total market value
- ₩138T
- Day's move
- −0.64%
- As of
- Oct 29, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Samsung Epis Holdings | Oct 28Preliminary | ₩442B | +0.3% | ₩133B | +2.8% | +125.8% | 30.0%29.3% |
| CKD Bio | Oct 30Preliminary | ₩29B | −14.0% | −₩6B | Bigger loss | Bigger loss | −20.4%−4.3% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| ISU Abxis | Expected around Nov 6 | ||||||
| Aprogen Biologics | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Celltrion Pharm | Expected around Nov 14 | ||||||
| Komipharm International | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| Prestige BioPharma | Expected around Nov 28 | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 29, 2026- Above 20-day average
- 22.2%
- Above 60-day average
- 22.2%
- RSI above 70
- 0%
- RSI below 30
- 22.2%
- 52-week highs
- 0
- 52-week lows
- 0
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biosimilars theme covers 9 Korean stocks, and only 22.2% of them are trading above both their 20-day and 60-day averages. The group has no names at 52-week highs or lows, and its RSI extreme count shows one member near oversold territory at 22.2 with none overbought. The equal-weighted member index sits below its cloud with an RSI of 35.2, and its short- and medium-term signals both read bearish, with 7 of 9 members on the bearish side in each window.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
ETFs for this theme
All ETFs →AUM · Flow 1w
Biosimilars
−4.89%바이오시밀러
Biosimilars are copies of biologic drugs, which are complex medicines made from living cells, that are shown to be highly similar to an already-approved reference product in quality, safety, and efficacy. Korean investors group the theme together because several domestic companies, including Samsung Biologics, Celltrion, and Hanmi-linked developers, have built large manufacturing or development capabilities in this area. Because the sector sits at the intersection of pharmaceuticals, contract manufacturing, and patent-expiry timelines, the theme is often discussed as a single category even though individual companies differ in business models.
13 companies · 1 up · 0 flat · 12 down
- Traded value
- ₩213B
- Value vs 20-day average
- 0.64×
- Top gainer
- Samsung Biologics +0.37%
- Largest company
- Samsung Biologics ₩63T
Companies in this theme
| Company | Price | Weekly | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,366,000 | +0.37% | ₩58B | ₩63T | 6.88% |
Celltrion068270 · KOSPI | ₩189,300 | −2.57% | ₩71B | ₩44T | 7.28% |
Samsung Epis Holdings0126Z0 · KOSPI | ₩307,000 | −6.40% | ₩12B | ₩7.6T | 5.70% |
Prestige BioPharma950210 · KOSPI | ₩4,155 | −21.46% | ₩441M | ₩250B | 0.15% |
CKD Bio063160 · KOSPI | ₩12,350 | −3.14% | ₩135M | ₩68B | 0.62% |
Aprogen Biologics003060 · KOSPI | ₩1,380 | −1.99% | ₩124M | ₩42B | 0.08% |
Source: KRX statistical information